Trial · NCT03080935
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 48
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event | Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | 686 | Participants | ||
| Number of Participants Who Experienced an Adverse Event | Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | 810 | Participants | ||
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Week 12 | -66.32 | Standard Deviation 26.88 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Week 12 | -67.24 | Standard Deviation 25.23 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Week 24 | -66.48 | Standard Deviation 27.52 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Week 24 | -66.47 | Standard Deviation 28.11 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Week 48 | -62.61 | Standard Deviation 26.60 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Week 48 | -63.45 | Standard Deviation 26.03 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Week 72 | -65.58 | Standard Deviation 28.13 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Week 72 | -65.33 | Standard Deviation 28.42 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Week 96 | -64.58 | Standard Deviation 27.01 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Week 96 | -63.43 | Standard Deviation 28.80 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Week 120 | -64.26 | Standard Deviation 28.31 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Week 120 | -63.10 | Standard Deviation 29.56 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Week 144 | -66.79 | Standard Deviation 29.22 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Week 144 | -65.13 | Standard Deviation 31.96 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Week 168 | -65.28 | Standard Deviation 27.55 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Week 168 | -63.55 | Standard Deviation 29.60 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Week 192 | -65.02 | Standard Deviation 27.93 | Percent Change |
| Percent Change of Low-density Lipoprotein Cholesterol (LDL-C) From Baseline at Each Scheduled Visit | Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study | Week 192 | -62.46 | Standard Deviation 26.39 | Percent Change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03080935/results